| Literature DB >> 29024810 |
Si-Jian Pan1, Jie Ren1, Hong Jiang1, Wei Liu2, Liang-Yun Hu2, Yi-Xin Pan2, Bomin Sun2, Qing-Fang Sun3, Liu-Guan Bian4.
Abstract
Melanoma antigen A6 (MAGEA6)/TRIM28 complex is a cancer-specific ubiquitin ligase, which degradates tumor suppressor protein AMP-activated protein kinase (AMPK). We show that MAGEA6 is uniquely expressed in human glioma tissues and cells, which is correlated with AMPKα1 downregulation. It is yet absent in normal brain tissues and human astrocytes/neuronal cells. MAGEA6 knockdown by targeted-shRNA in glioma cells restored AMPKα1 expression, causing mTORC1 in-activation and cell death/apoptosis. Reversely, AMPKα1 knockdown or mutation ameliorated glioma cell death by MAGEA6 shRNA. In vivo, Glioma xenograft tumor growth in mice was largely inhibited following expressing MAGEA6 shRNA. AMPKα1 upregulation and mTORC1 inhibition were observed in MAGEA6 shRNA-bearing xenograft tissues. Collectively, MAGEA6 promotes glioma cell survival possibly via targeting AMPKα1.Entities:
Keywords: AMPK; Glioma; MAGEA6; mTOR and oncotarget
Mesh:
Substances:
Year: 2017 PMID: 29024810 DOI: 10.1016/j.canlet.2017.09.051
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679